
Coya Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US22407B1089 (COYA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). Read full profile
Stock price
Fundamentals
- Net revenue
€363.32K - Gross margin
96.8% - EBIT
-€5.52B - EBIT margin
-1,518,643.2% - Net income
-€5.24B - Net margin
-1,442,718.7%
Statement period: - (published )
Dividends
No dividend payouts
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |